RNA

Atrium Therapeutics (RNA) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.

SEC Filings

Atrium Therapeutics Amends 8-K: 21,571,507 Shares Will Be Outstanding After Private Placement

An 8-K/A fixes the post-offering share count, which includes make-whole awards tied to the Avidity Biosciences spin-off.

Deals

Atrium Therapeutics Agrees To Sell About $50 Million Of Stock At $7.93, Says Cash Now Lasts Through 2028

The 8-K describes a private placement with Casdin, Aberdeen and others, plus pre-funded warrants and a 50-day deadline for a resale filing.